Creative medical technology holdings announces positive top-line study results for chronic lower back pain utilizing its stemspine® procedure using allostem™ allogenic cell line

Study demonstrated significant efficacy and no serious adverse events phoenix , may 18, 2023 /prnewswire/ -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced positive top line pilot study results for the stemspine® procedure using allostem™ to treat chronic lower back pain.  the data demonstrated significant efficacy and no serious adverse events using the stemspine® ultrasound guided non-surgical procedure for treating chronic lower back pain.
CELZ Ratings Summary
CELZ Quant Ranking